Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Videos

Harry Yoon, MD and Nabil Saba, MD, FACP, discuss recent data on novel regimens for first-line treatment of advanced/metastatic ESCC, including the immunotherapy regimen tislelizumab.

Nabil Saba, MD, FACP and Harry Yoon, MD, briefly review the incidence of esophageal squamous cell carcinoma (ESCC), and describe how many patients present with unresectable locally advanced or metastatic disease in their clinical practice.

Trends in ESCC Incidence and Observations from Clinical Practice

Expert perspectives on the process of biomarker testing, including PD-L1 testing, for patients with unresectable locally advanced or metastatic ESCC.

Approaches to Biomarker Testing for ESCC

Drs Saba and Yoon share how a patient’s biomarker testing results typically affect prognosis and how they may influence subsequent treatment decision-making.

The Impact of Biomarker Results on Prognosis and Treatment Decision-Making

A focused discussion on the available first-line treatment options for advanced/metastatic ESCC.

First-Line Options for Advanced/Metastatic Disease

Drs Saba and Yoon share the factors they consider when choosing among available first-line regimens for ESCC, including clinical trial data and the patient’s PD-L1 expression status.

Insights on ESCC First-Line Treatment Selection

Dr Yoon introduces tislelizumab, an anti-PD-1 immunotherapy regimen being investigated as a first-line ESCC treatment option in combination with chemotherapy, and discusses recent conference data from the RATIONALE-306 trial.

RATIONALE-306 Data on Tislelizumab in ESCC

Drs Saba and Yoon reflect on how the potential FDA approval and availability of tislelizumab might change first-line ESCC treatment paradigms in the future.

The Potential Impact of Tislelizumab on First-Line ESCC Treatment

A review of other ongoing trials and emerging treatment regimens in the space and a summary of takeaways from trials on other squamous cell cancers that may also be applied to ESCC.

Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

Trends in ESCC Incidence and Observations from Clinical Practice

EP: 1.Trends in ESCC Incidence and Observations from Clinical Practice

EP: 2.Approaches to Biomarker Testing for ESCC

EP: 3.The Impact of Biomarker Results on Prognosis and Treatment Decision-Making

EP: 4.First-Line Options for Advanced/Metastatic Disease

EP: 5.Insights on ESCC First-Line Treatment Selection

EP: 6.RATIONALE-306 Data on Tislelizumab in ESCC

EP: 7.The Potential Impact of Tislelizumab on First-Line ESCC Treatment

EP: 8.Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers

EP: 9.A Look Towards the Future of ESCC

Latest Conference Coverage